BACKGROUND: Despite the benefits of reperfusion in limiting myocardial injury, the infarct size continues to expand after reperfusion because of secondary inflammatory injury. Plasma-derived alpha-1 antitrypsin (AAT) inhibits the inflammatory injury in myocardial ischemia and reperfusion. To explore the effects of plasma-derived AAT on the inflammatory response to ischemia-reperfusion injury, we analyzed time-to-reperfusion and enzymatic infarct size estimates in a post hoc analysis of the VCU-α1RT clinical trial (clinicaltrials.gov NCT01936896). METHODS:Ten patients with ST-segment elevation acute myocardial infarction (STEMI) were enrolled in an open-label, single-arm treatment study of Prolastin C, plasma-derived AAT, at 60 mg/kg infused intravenously within 12 hours of reperfusion. Biomarkers were measured serially over the first 72 hours, and patients were followed clinically for the occurrence of new-onset heart failure, recurrent MI, or death. Twenty patients with STEMI who had been enrolled in previous randomized trials with identical inclusion/exclusion criteria and had been assigned toplacebo served as historical controls. RESULTS: Time to percutaneous coronary intervention and time to drug did not significantly differ between groups. AAT-treated patients had a significantly shorter time-to-peak creatine kinase myocardial band (CK-MB) values (525 [480-735] vs. 789 [664-959] minute, P = 0.005) and CK-MB area under the curve (from 1204 [758-2728] vs. 2418 [1551-4289] U·day, P = 0.035), despite no differences in peak CK-MB (123 [30-196] vs. 123 [71-213] U/mL, P = 0.71). CONCLUSIONS: A single administration of Prolastin C given hours after reperfusion in patients with STEMI led to a significant shorter time to peak and area under the curve for CK-MB, despite similar peak CK-MB values. These preliminary data support the hypothesis that Prolastin C shortens the duration of the ischemia-reperfusion injury in patients with STEMI.
RCT Entities:
BACKGROUND: Despite the benefits of reperfusion in limiting myocardial injury, the infarct size continues to expand after reperfusion because of secondary inflammatory injury. Plasma-derived alpha-1 antitrypsin (AAT) inhibits the inflammatory injury in myocardial ischemia and reperfusion. To explore the effects of plasma-derived AAT on the inflammatory response to ischemia-reperfusion injury, we analyzed time-to-reperfusion and enzymatic infarct size estimates in a post hoc analysis of the VCU-α1RT clinical trial (clinicaltrials.gov NCT01936896). METHODS: Ten patients with ST-segment elevation acute myocardial infarction (STEMI) were enrolled in an open-label, single-arm treatment study of Prolastin C, plasma-derived AAT, at 60 mg/kg infused intravenously within 12 hours of reperfusion. Biomarkers were measured serially over the first 72 hours, and patients were followed clinically for the occurrence of new-onset heart failure, recurrent MI, or death. Twenty patients with STEMI who had been enrolled in previous randomized trials with identical inclusion/exclusion criteria and had been assigned to placebo served as historical controls. RESULTS: Time to percutaneous coronary intervention and time to drug did not significantly differ between groups. AAT-treated patients had a significantly shorter time-to-peak creatine kinase myocardial band (CK-MB) values (525 [480-735] vs. 789 [664-959] minute, P = 0.005) and CK-MB area under the curve (from 1204 [758-2728] vs. 2418 [1551-4289] U·day, P = 0.035), despite no differences in peak CK-MB (123 [30-196] vs. 123 [71-213] U/mL, P = 0.71). CONCLUSIONS: A single administration of Prolastin C given hours after reperfusion in patients with STEMI led to a significant shorter time to peak and area under the curve for CK-MB, despite similar peak CK-MB values. These preliminary data support the hypothesis that Prolastin C shortens the duration of the ischemia-reperfusion injury in patients with STEMI.
Authors: Antonio Abbate; Michael C Kontos; John D Grizzard; Giuseppe G L Biondi-Zoccai; Benjamin W Van Tassell; Roshanak Robati; Lenore M Roach; Ross A Arena; Charlotte S Roberts; Amit Varma; Christopher C Gelwix; Fadi N Salloum; Andrea Hastillo; Charles A Dinarello; George W Vetrovec Journal: Am J Cardiol Date: 2010-04-02 Impact factor: 2.778
Authors: Robert L McNamara; Yongfei Wang; Jeph Herrin; Jeptha P Curtis; Elizabeth H Bradley; David J Magid; Eric D Peterson; Martha Blaney; Paul D Frederick; Harlan M Krumholz Journal: J Am Coll Cardiol Date: 2006-05-15 Impact factor: 24.094
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White; Kristian Thygesen; Joseph S Alpert; Harvey D White; Allan S Jaffe; Hugo A Katus; Fred S Apple; Bertil Lindahl; David A Morrow; Bernard R Chaitman; Peter M Clemmensen; Per Johanson; Hanoch Hod; Richard Underwood; Jeroen J Bax; Jeroen J Bonow; Fausto Pinto; Raymond J Gibbons; Keith A Fox; Dan Atar; L Kristin Newby; Marcello Galvani; Christian W Hamm; Barry F Uretsky; Ph Gabriel Steg; William Wijns; Jean-Pierre Bassand; Phillippe Menasche; Jan Ravkilde; E Magnus Ohman; Elliott M Antman; Lars C Wallentin; Paul W Armstrong; Maarten L Simoons; James L Januzzi; Markku S Nieminen; Mihai Gheorghiade; Gerasimos Filippatos; Russell V Luepker; Stephen P Fortmann; Wayne D Rosamond; Dan Levy; David Wood; Sidney C Smith; Dayi Hu; Jose-Luis Lopez-Sendon; Rose Marie Robertson; Douglas Weaver; Michal Tendera; Alfred A Bove; Alexander N Parkhomenko; Elena J Vasilieva; Shanti Mendis; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Joao Morais; Carlos Aguiar; Wael Almahmeed; David O Arnar; Fabio Barili; Kenneth D Bloch; Ann F Bolger; Hans Erik Botker; Biykem Bozkurt; Raffaele Bugiardini; Christopher Cannon; James de Lemos; Franz R Eberli; Edgardo Escobar; Mark Hlatky; Stefan James; Karl B Kern; David J Moliterno; Christian Mueller; Aleksandar N Neskovic; Burkert Mathias Pieske; Steven P Schulman; Robert F Storey; Kathryn A Taubert; Pascal Vranckx; Daniel R Wagner Journal: J Am Coll Cardiol Date: 2012-09-05 Impact factor: 24.094
Authors: Zubin J Eapen; W H Wilson Tang; G Michael Felker; Adrian F Hernandez; Kenneth W Mahaffey; A Michael Lincoff; Matthew T Roe Journal: Circ Cardiovasc Qual Outcomes Date: 2012-07-01
Authors: Stefano Toldo; Ignacio M Seropian; Eleonora Mezzaroma; Benjamin W Van Tassell; Fadi N Salloum; Eli C Lewis; Norbert Voelkel; Charles A Dinarello; Antonio Abbate Journal: J Mol Cell Cardiol Date: 2011-05-12 Impact factor: 5.000
Authors: Antonio Abbate; Benjamin Wallace Van Tassell; Sanah Christopher; Nayef Antar Abouzaki; Chiara Sonnino; Claudia Oddi; Salvatore Carbone; Ryan David Melchior; Michael Lucas Gambill; Charlotte Susan Roberts; Michael Christopher Kontos; Mary Ann Peberdy; Stefano Toldo; George Wayne Vetrovec; Giuseppe Biondi-Zoccai; Charles Anthony Dinarello Journal: Am J Cardiol Date: 2014-10-13 Impact factor: 2.778
Authors: Antonio Abbate; Benjamin Wallace Van Tassell; Giuseppe Biondi-Zoccai; Michael Christopher Kontos; John Dallas Grizzard; Debra Whittaker Spillman; Claudia Oddi; Charlotte Susan Roberts; Ryan David Melchior; George Herman Mueller; Nayef Antar Abouzaki; Lenore Rosemary Rengel; Amit Varma; Michael Lucas Gambill; Raquel Appa Falcao; Norbert Felix Voelkel; Charles Anthony Dinarello; George Wayne Vetrovec Journal: Am J Cardiol Date: 2013-02-27 Impact factor: 2.778
Authors: Renato D Lopes; Yuliya Lokhnygina; Victor Hasselblad; Kristin L Newby; Eric Yow; Christopher B Granger; Paul W Armstrong; Judith S Hochman; James S Mills; Witold Ruzyllo; Kenneth W Mahaffey Journal: Trials Date: 2013-05-02 Impact factor: 2.279
Authors: Wendy M McKimpson; Yun Chen; James A Irving; Min Zheng; Jeremy Weinberger; Wilson Lek Wen Tan; Zenia Tiang; Alistair M Jagger; Streamson C Chua; Jeffrey E Pessin; Roger S-Y Foo; David A Lomas; Richard N Kitsis Journal: Dev Cell Date: 2021-03-04 Impact factor: 12.270
Authors: Nicola Potere; Marco Giuseppe Del Buono; Giampaolo Niccoli; Filippo Crea; Stefano Toldo; Antonio Abbate Journal: Int J Mol Sci Date: 2019-01-28 Impact factor: 5.923
Authors: George F Wohlford; Leo F Buckley; Dinesh Kadariya; Taeshik Park; Juan Guido Chiabrando; Salvatore Carbone; Virginia Mihalick; Matthew S Halquist; Adam Pearcy; Dana Austin; Cohava Gelber; Antonio Abbate; Benjamin Van Tassell Journal: PLoS One Date: 2021-05-06 Impact factor: 3.240
Authors: Antonio Abbate; Cory R Trankle; Leo F Buckley; Michael J Lipinski; Darryn Appleton; Dinesh Kadariya; Justin M Canada; Salvatore Carbone; Charlotte S Roberts; Nayef Abouzaki; Ryan Melchior; Sanah Christopher; Jeremy Turlington; George Mueller; James Garnett; Christopher Thomas; Roshanak Markley; George F Wohlford; Laura Puckett; Horacio Medina de Chazal; Juan G Chiabrando; Edoardo Bressi; Marco Giuseppe Del Buono; Aaron Schatz; Chau Vo; Dave L Dixon; Giuseppe G Biondi-Zoccai; Michael C Kontos; Benjamin W Van Tassell Journal: J Am Heart Assoc Date: 2020-03-03 Impact factor: 6.106